Comments
Loading...

BridgeBio Pharma

BBIONASDAQ
Logo brought to you by Benzinga Data
$25.48
2.078.84%
At close: -
$25.48
00.00%
After Hours: Nov 1, 5:16 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$70.00
Lowest Price Target1
$19.00
Consensus Price Target1
$43.17

BridgeBio Pharma (NASDAQ:BBIO) Stock, Analyst Ratings, Price Targets, Forecasts

BridgeBio Pharma Inc has a consensus price target of $43.17 based on the ratings of 20 analysts. The high is $70 issued by Cantor Fitzgerald on September 16, 2024. The low is $19 issued by SVB Leerink on January 23, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Leerink Partners, and Scotiabank on October 25, 2024, October 17, 2024, and October 16, 2024, respectively. With an average price target of $44.33 between HC Wainwright & Co., Leerink Partners, and Scotiabank, there's an implied 73.99% upside for BridgeBio Pharma Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jul
2
Aug
3
Sep
1
Oct
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Leerink Partners
Scotiabank
Cantor Fitzgerald
B of A Securities

1calculated from analyst ratings

Analyst Ratings for BridgeBio Pharma

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for BridgeBio Pharma (BBIO) stock?

A

The latest price target for BridgeBio Pharma (NASDAQ:BBIO) was reported by HC Wainwright & Co. on October 25, 2024. The analyst firm set a price target for $43.00 expecting BBIO to rise to within 12 months (a possible 68.76% upside). 37 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ:BBIO) was provided by HC Wainwright & Co., and BridgeBio Pharma reiterated their buy rating.

Q

When was the last upgrade for BridgeBio Pharma (BBIO)?

A

There is no last upgrade for BridgeBio Pharma

Q

When was the last downgrade for BridgeBio Pharma (BBIO)?

A

The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on October 25, 2024 so you should expect the next rating to be made available sometime around October 25, 2025.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $43.00 to $43.00. The current price BridgeBio Pharma (BBIO) is trading at is $25.48, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch